The Administrative, Biostatistics, and Clinical Support Core (A) will provide the infrastructure support for the basic and clinical research components of this program. The Administrative component of the core will coordinate the overall interactions among the research projects and core facilities. This will include preparation of manuscripts and progress reports and maintaining the ongoing calendar of weekly research meetings among the program's investigators to facilitate regular review of the progress of the component projects. In addition, this component of the core will maintain the calendar of biweekly strategic planning meetings among the project leaders to discuss issues related to the long-range goals of the individual projects and their interactions with the overall program, and will coordinate periodic oversight of the program by the internal and external advisory groups composed of scientists with expertise relevant to the program. The administrative component will also be responsible for overall budgetary issues of the program, for coordinating interactions between the program and other administrative entities within the institution, and for providing logistical and scientific support to facilitate progress of the component projects. This core will promote the involvement and interactions of each project with a biostatistician, who has worked closely with the investigators of this program from its outset. This Biostatistics component of the core will ensure that appropriate statistical parameters are incorporated in the design of the studies of the program, so that in vitro, animal, and patient resources are used efficiently, and that rigorous methods are applied for the interpretation and reporting of the results of preclinical and clinical studies. This core will also coordinate the Clinical Support for therapeutic studies conducted within the context of this program by facilitating timely submission of protocols for institutional peer review, maintaining compliance with institutional and federal guidelines, and ensuring that the clinical aspects of this program are integrated seamlessly with the extensive existing resources available within the University of Pittsburgh Cancer Institute. Relevance: This core will provide the essential administrative, biostatistical and clinical support expertise needed to facilitate the research mission of the projects and other cores within this program.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Program Projects (P01)
Project #
5P01NS040923-10
Application #
8377649
Study Section
National Institute of Neurological Disorders and Stroke Initial Review Group (NSD)
Project Start
Project End
2014-02-28
Budget Start
2012-03-01
Budget End
2013-02-28
Support Year
10
Fiscal Year
2012
Total Cost
$166,085
Indirect Cost
$56,458
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Furtado, Andre D; Ceschin, Rafael; Bl├╝ml, Stefan et al. (2017) Neuroimaging of Peptide-based Vaccine Therapy in Pediatric Brain Tumors: Initial Experience. Neuroimaging Clin N Am 27:155-166
Pollack, Ian F; Jakacki, Regina I; Butterfield, Lisa H et al. (2016) Immune responses and outcome after vaccination with glioma-associated antigen peptides and poly-ICLC in a pilot study for pediatric recurrent low-grade gliomas. Neuro Oncol 18:1157-68
Jane, Esther P; Premkumar, Daniel R; Cavaleri, Jonathon M et al. (2016) Dinaciclib, a Cyclin-Dependent Kinase Inhibitor Promotes Proteasomal Degradation of Mcl-1 and Enhances ABT-737-Mediated Cell Death in Malignant Human Glioma Cell Lines. J Pharmacol Exp Ther 356:354-65
Pollack, Ian F; Jakacki, Regina I; Butterfield, Lisa H et al. (2016) Antigen-specific immunoreactivity and clinical outcome following vaccination with glioma-associated antigen peptides in children with recurrent high-grade gliomas: results of a pilot study. J Neurooncol 130:517-527
Foster, Kimberly A; Jane, Esther P; Premkumar, Daniel R et al. (2015) NVP-BKM120 potentiates apoptosis in tumor necrosis factor-related apoptosis-inducing ligand-resistant glioma cell lines via upregulation of Noxa and death receptor 5. Int J Oncol 47:506-16
Ceschin, R; Kurland, B F; Abberbock, S R et al. (2015) Parametric Response Mapping of Apparent Diffusion Coefficient as an Imaging Biomarker to Distinguish Pseudoprogression from True Tumor Progression in Peptide-Based Vaccine Therapy for Pediatric Diffuse Intrinsic Pontine Glioma. AJNR Am J Neuroradiol 36:2170-6
Mazzacurati, Lucia; Marzulli, Marco; Reinhart, Bonnie et al. (2015) Use of miRNA response sequences to block off-target replication and increase the safety of an unattenuated, glioblastoma-targeted oncolytic HSV. Mol Ther 23:99-107
Premkumar, Daniel R; Jane, Esther P; Pollack, Ian F (2015) Cucurbitacin-I inhibits Aurora kinase A, Aurora kinase B and survivin, induces defects in cell cycle progression and promotes ABT-737-induced cell death in a caspase-independent manner in malignant human glioma cells. Cancer Biol Ther 16:233-43
Ohkuri, Takayuki; Ghosh, Arundhati; Kosaka, Akemi et al. (2014) STING contributes to antiglioma immunity via triggering type I IFN signals in the tumor microenvironment. Cancer Immunol Res 2:1199-208
Foster, Kimberly A; Jane, Esther P; Premkumar, Daniel R et al. (2014) Co-administration of ABT-737 and SAHA induces apoptosis, mediated by Noxa upregulation, Bax activation and mitochondrial dysfunction in PTEN-intact malignant human glioma cell lines. J Neurooncol 120:459-72

Showing the most recent 10 out of 105 publications